Company Announcements

Abcam established direct service in Australia and New Zealand in August.

In September, Abcam announced that Peter Keen will not seek reelection to its Board.

Abcam entered into an exclusive license, supply and distribution agreement with Australia’s Children’s Cancer Institute for multidrug-resistance protein 4 inhibitors, Ceefourin 1 and Ceefourin 2.

Nirmidas Biotech raised $2 million in seed round funding in August to commercialize its fluorescence-enhancing plasmonic gold technology.

Bio-Techne licensed the Medical Research Council Laboratory of Molecular Biology’s GOPAL (genetically encoded orthogonal protection and activate ligation) technology.

In September, Corning entered into an agreement with BioLamina to manufacture and package the Recombinant Laminin-521 pluripotent stem-cell and neural stem-cell growth matrix.

Sigma-Aldrich and the University of Michigan Medical School’s Vector Core entered into a gene-editing partnership.

Xconomy.com reported in September that Allele Biotechnology & Pharmaceuticals raised $7 million in its first round of funding from institutions.

LINK appointed Dr. David Ricketts as CEO, effective October 20. Most recently, he was CEO of FibromEd.

Product Introductions

VICAM introduced the Afla-V AQUA Strip Tests, which allow the tests to be performed with fewer steps and without the need for organic solvents.

Romer Labs released the AgraStrip Total Aflatoxin quantitative WATEX test kit, which is solvent free with an eight-minute time to result.

Innova Biosciences launched InnovaGOLD gold nanoparticles.

AMSBIO introduced a custom phospho-specific-antibody–production service.

In September, AMSBIO launched the Dicer siRNA Generation Kit.

Abcam introduced an exclusive range of conjugated antibodies for imaging applications.

Agilent Technologies launched SureGuide, the first in a new series of kits to advance genome editing and synthetic biology. The workflow includes a SureGuide Cas9 Nuclease Kit, SureGuide gRNA Synthesis Kit and SureGuide gRNA Control Kit.

Life Technologies introduced the GeneArt CRISPR products, which leverage the type II CRISPER/Cas9 system for genome editing. The product portfolio includes GeneArt CRISPR Nuclease mRNA and GeneArt CRISPR Nuclease Vector Kits.